News
AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in non-muscle invasive bladder cancer (NMIBC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback